Symposium on Acute Medicine

Managing side effects of cancer immunotherapy for the acute physician

Abstract

Immunotherapy is a novel type of anti-cancer treatment that works by upregulating the host's immune system to fight against cancer cells. Landmark immunotherapy trials have demonstrated improvements in response rates and survival compared to cytotoxic chemotherapy. Specific immunotherapies known as checkpoint inhibitors are now routinely used in a range of cancers including melanoma, lung, renal and urological cancers. Immunotherapies are associated with immune-related adverse events which are very different to those seen with traditional cytotoxic chemotherapies. This can present a new challenge to oncologists, acute physicians and the wider team of health-care professionals who look after patients receiving immunotherapy. Generally, these side effects are easily managed but some, if untreated, can be subtle and potentially life-threatening. Patients on immunotherapy may present to a wide variety of medical professionals including the emergency department, primary care and general medical admissions units. It is therefore vital that there is increased awareness and education to identify and manage side effects of immunotherapy effectively.

References

Ahn MA, Gandhi L, Hamid O et al.. Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2015 26(suppl_9):125–147. https://doi.org/https://doi.org/10.1093/annonc/mdv532 Crossref, Google Scholar
Beck KE, Blansfield JA, Tran KQ et al.. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20;24(15):2283–2289. https://doi.org/https://doi.org/10.1200/JCO.2005.04.5716 Crossref, Medline, Google Scholar
Doherty GJ, Duckworth AM, Davies SE et al.. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017 Oct;2(4):e000268. https://doi.org/https://doi.org/10.1136/esmoopen-2017-000268 Crossref, Medline, Google Scholar
Eggermont AMM, Chiarion-Sileni V, Grob JJ et al.. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016 Nov 10;375(19):1845–1855. https://doi.org/https://doi.org/10.1056/NEJMoa1611299 Crossref, Medline, Google Scholar
Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011 Jan 01;16(1):5–24. https://doi.org/https://doi.org/10.1634/theoncologist.2010-0190 Crossref, Medline, Google Scholar
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 01;28 suppl_4:iv119–iv142. https://doi.org/https://doi.org/10.1093/annonc/mdx225 Crossref, Medline, Google Scholar
Horvat TZ, Adel NG, Dang TO et al.. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015 Oct;33(28):3193–3198. https://doi.org/https://doi.org/10.1200/JCO.2015.60.8448 Crossref, Medline, Google Scholar
Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2017 Jul 26. https://doi.org/https://doi.org/10.1097/COC.0000000000000374 Crossref, Medline, Google Scholar
Ibrahim RA, Berman DM, DePril V et al.. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma [abstract]. J Clin Oncol. 2011; 29:15(suppl 8583). Google Scholar
Khunger M, Rakshit S, Pasupuleti V et al.. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chest. 2017 Aug;152(2):271–281. https://doi.org/https://doi.org/10.1016/j.chest.2017.04.177 Crossref, Medline, Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 02;373(1):23–34. https://doi.org/https://doi.org/10.1056/NEJMoa1504030 Crossref, Medline, Google Scholar
Lord JD, Hackman RC, Moklebust A et al.. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci. 2010 May;55(5):1396–1405. https://doi.org/https://doi.org/10.1007/s10620-009-0839-8 Crossref, Medline, Google Scholar
Marthey L, Mateus C, Mussini C et al.. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn's Colitis. 2016 Apr;10(4):395–401. https://doi.org/https://doi.org/10.1093/ecco-jcc/jjv227 Crossref, Google Scholar
Naidoo J, Wang X, Woo KM et al.. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017 Mar;35(7):709–717. https://doi.org/https://doi.org/10.1200/JCO.2016.68.2005 Crossref, Medline, Google Scholar
Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer. JAMA Oncol. 2016 Dec 01;2(12):1607–1616. https://doi.org/https://doi.org/10.1001/jamaoncol.2016.2453 Crossref, Medline, Google Scholar
Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016 Jul;28(4):278–287. https://doi.org/https://doi.org/10.1097/CCO.0000000000000293 Crossref, Medline, Google Scholar
UK Oncology Nursing Society. 2018. Acute Oncology Initial Management Guidelines. (accessed 29 June 2018) https://az659834.vo.msecnd.net/eventsairwesteuprod/production-succinct-public/e80a54a0570a470bb0cf1ab07a7644e7 Google Scholar
Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. Int J Cancer. 2017 Sep 01;141(5):1018–1028. https://doi.org/https://doi.org/10.1002/ijc.30678 Crossref, Medline, Google Scholar
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 05;377(14):1345–1356. https://doi.org/https://doi.org/10.1056/NEJMoa1709684 Crossref, Medline, Google Scholar

2 July 2018Volume 79Issue 7

ISSN (print): 1750-8460
ISSN (online): 1759-7390

Metrics

Downloaded 14 times

History

Published online 11 July 2018

Published in print 2 July 2018

Information

PDF download